+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma



Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma



International Journal of Cancer 98(6): 916-922, 20 April



The effect of highly active antiretroviral therapy (HAART) on survival in HIV-infected patients with Kaposi sarcoma (KS) or non-Hodgkin lymphoma (NHL) is unknown. Our study examines survival after HAART for these 2 malignancies. Analyses were performed using data from 387 HIV-infected men in the Multicenter AIDS Cohort Study (MACS) after a diagnosis of either KS or NHL in 1990-99. Potential prognostic factors, including HAART, were evaluated in univariate analyses using Kaplan-Meier survival curves and log-rank tests. Multivariate survival analyses were conducted using Cox's time-dependent proportional hazards models, adjusting for CD4(+) cell levels at the time of cancer diagnosis and other covariates. Forty-three of 287 KS patients (15%) and 13 of 100 NHL patients (13%) had been treated with HAART. HAART treatment was associated with improved survival for KS and NHL patients (log-rank p = 0.0001 for each group). In multivariate analyses, HAART was associated with an 81% reduced risk of death among KS patients [relative hazard (RH) 0.19, 95% confidence limits (CL) (0.08, 0.45)], compared to those not exposed to HAART and an 84% reduced risk [RH 0.16, 95% CL (0.04, 0.64)] among NHL patients. Relative hazards estimates were similar for those with HAART initiation before and after NHL diagnosis. The use of HAART prolongs overall survival among HIV-positive men diagnosed with KS and NHL. HAART appears to be effective in improving survival even when initiated after the diagnosis of NHL and KS.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010525553

Download citation: RISBibTeXText

PMID: 11948473

DOI: 10.1002/ijc.10274


Related references

Reduced incidence of Kaposi's sarcoma and of systemic non-hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. International Journal of Cancer 103(1): 142-144, 2003

The impact of Kaposi sarcoma and non-Hodgkin lymphoma on mortality of people with AIDS in the highly active antiretroviral therapies era. Cancer Epidemiology 34(3): 257-261, 2010

Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. Journal of Clinical Oncology 19(18): 3848-3851, 2001

Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy. HIV Clinical Trials 4(2): 107-114, 2003

Highly active antiretroviral therapy does not protect against Kaposi's sarcoma in HIV-infected individuals. Aids 14(14): 2217-2218, 2000

A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes 60(2): 150-157, 2012

Regression of Kaposi's sarcoma lesions following highly active antiretroviral therapy in an HIV-infected patient. International Journal of Std and Aids 19(11): 786-788, 2008

Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. Aids 18(12): 1737-1740, 2004

Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 98(12): 3406-3412, 2001

The interaction between smoking status and highly active antiretroviral therapy HAART use on the risk of Kaposi’s sarcoma KS in a cohort of HIV-infected men. British Journal of Cancer 108(5): 1173-1177, 2013

Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. Journal of Clinical Oncology 22(3): 399-402, 2004

Systemic non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 99(11): 4250-4251, 2002

Patterns of lymphotropic herpesvirus viraemia in HIV-infected patients with Kaposi's sarcoma treated with highly active antiretroviral therapy and liposomal daunorubicin. Aids 14(14): 2215-2217, 2000

Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. Aids 17(1): 81-87, 2003

Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma. Acta Oncologica 41(2): 192-196, 2002